Aptamer-Engineered Human Islets

Aptamer-Engineered Human Islets represent a novel cell therapy approach aimed at improving the success of islet transplantation, particularly in the context of Type 1 Diabetes. This therapeutic strategy involves modifying human pancreatic islets, which are clusters of cells responsible for insulin production, with specific aptamers. These aptamers are designed to target and block key pro-inflammatory mediators such as Interleukin 1 beta (IL-1β) and Tumor Necrosis Factor-alpha (TNFα), as well as pro-coagulant factors like Factor VIIa (FVIIa). The primary mechanism of action is to mitigate the instant blood-mediated inflammatory reaction (IBMIR), a significant challenge that often leads to early graft failure in islet transplantation. By reducing inflammation and inhibiting coagulation at the transplant site, the aptamer-engineered islets are expected to enhance engraftment and survival of the transplanted cells, thereby improving long-term outcomes for patients. The development is currently in preclinical stages, with in vitro and in vivo studies in animal models demonstrating the potential of this approach.